131 results
8-K
EX-99.1
HRTX
Heron Therapeutics Inc
13 May 21
Heron Therapeutics Announces U.S. FDA Approval of ZYNRELEF™ (HTX-011) for the Management of Postoperative Pain for up to 72 Hours
8:25am
Advancing Postoperative Pain Management May 2021
Executive Summary: Go-to-Market Strategy Strategic Imperatives Establish ZYNRELEF as a new class and best … choice for postoperative pain Raise the bar with ZYNRELEF’s superior value proposition to expedite access Highly focused targeting strategy
8-K
EX-99.2
HRTX
Heron Therapeutics Inc
2 Oct 19
Heron Announces Positive Topline Results from Phase 3b Clinical Study of HTX-011 in Total Knee Arthroplasty
7:57am
Setting of Care Clearly differentiated strategy supported by building advocacy with pharmacy, surgeons, and anesthesiologists 52% Hospital Inpatient … robust platform and structure to support launch Significant unmet need and market opportunity Highly focused launch strategy to accelerate sales
8-K
EX-99.1
HRTX
Heron Therapeutics Inc
5 Mar 13
A.P. Pharma Appoints Jesse Hollingsworth
12:00am
) and Trade Strategy at Dendreon where he developed and implemented the company’s national GPO strategy. During this time, he was also responsible
8-K
EX-99.1
HRTX
Heron Therapeutics Inc
14 Dec 12
A.P. Pharma Names Mark S. Gelder, M.D. as Senior Vice President and Chief Medical Officer
12:00am
and pharmacovigilance at GE Healthcare Medical Diagnostics. During his tenure, he led the global medical affairs strategy, including preparation and execution … was the vice president, global medical affairs oncology for Bayer Healthcare Pharmaceuticals, and was responsible for the global medical strategy supporting
8-K
EX-99.2
HRTX
Heron Therapeutics Inc
13 Jan 20
Heron Therapeutics Highlights Progress in Pain Management and CINV Franchises
8:41am
Yes Yes Clinical Differentiation Yes – PS-80 free Yes – beat SOC Ease of Use High – IV push, infusion High - installation Price Strategy vs. Brand 20 … launch success Existing robust platform and structure to support launch Significant unmet need and market opportunity Highly focused launch strategy
8-K
9g2l2bgj
28 Feb 11
Departure of Directors or Certain Officers
12:00am
8-K
EX-99.1
0ab0dbgi08b333ln5q7m
20 Sep 11
This presentation contains "forward-looking statements" as defined by the Private
12:00am
8-K
EX-99.2
rpj3jxus39ylxkchbpf
19 Sep 22
Other Events
8:00am
8-K
EX-10.1
smcmubyjyy9sqda63ri
1 Jun 10
A.P. Pharma Announces Changes in Management and Hires Leading Consulting Practice to Lead FDA Review Process
12:00am
8-K
EX-99.1
1hejcf7t1 3j
1 Jun 10
A.P. Pharma Announces Changes in Management and Hires Leading Consulting Practice to Lead FDA Review Process
12:00am
8-K
EX-99.1
en4d 9j77
3 Oct 06
Entry into a Material Definitive Agreement
12:00am
8-K
EX-99.2
rb1g49ssic30 5qyq8
7 Jan 19
Heron Therapeutics Highlights Progress in Pain Management and CINV Franchises
8:36am
8-K
EX-99.1
pc5nzgi1dqebok0m7d4f
30 Jun 22
Heron Therapeutics Announces Restructuring and Cost Reduction Plan to Address Market Dynamics and Prepare for Long-Term Sustainability
8:40am
8-K
EX-99.1
s0cfwu
4 Jun 20
Regulation FD Disclosure
9:14am
8-K
EX-99.1
koaab jww9b7vp
1 Aug 07
A.p. Pharma Reports Second Quarter Financial Results
12:00am
424B4
zngdyhwhcf 36
25 Jun 04
Prospectus supplement with pricing info
12:00am
8-K/A
EX-99.1
skwnw
25 Jun 18
Other Events
4:01pm
8-K
EX-99.1
tuss0moeokycryv8dd1
21 Jun 18
Regulation FD Disclosure
8:11am
8-K
EX-99.1
64a1oe31i
5 Nov 20
Results of Operations and Financial Condition
8:40am